Shots:
- The companies collaborate to develop novel species-specific mAb biotherapeutics targeting a wide range of diseases in the veterinary species with an initial focus on dogs and cats
- The collaboration will utilize Invetx’s discovery platform, optimization technologies, and Ab expertise to develop veterinary biotherapeutics against selected targets for chronic & serious diseases in animals
- Boehringer Ingelheim will boost veterinary therapies through clinical and regulatory development to the commercialization of the products
Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Franchise India
The post Boehringer Ingelheim Signs an Agreement with Invetx to Develop and Commercialize Novel Veterinary Therapies first appeared on PharmaShots.
